Université de Paris, AP-HP, Hôpital Hôtel-Dieu, DMU Psychiatrie et Addictologie, Service de Psychiatrie de l'adulte, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Paris, France.
Université de Paris, AP-HP, Hôpital Hôtel-Dieu, Centre de Diagnostic et de Thérapeutique, Paris, France.
Curr Cardiol Rep. 2021 Jan 6;23(2):7. doi: 10.1007/s11886-020-01436-5.
To review evidence regarding the association between bipolar disorder and schizophrenia, henceforth referred to as severe mental disorders (SMD), and cardiovascular morbidity and mortality, its mechanisms, and the interventions to reduce this burden.
Much of the loss in life expectancy in people with SMD remains driven by cardiovascular mortality. Antipsychotics and mood stabilizers are associated with negative cardio-metabolic outcomes, but large inter-individual differences are observed, and not treating SMD might be associated with even greater cardiovascular mortality. Classical modifiable cardiovascular risk factors remained inadequately screened and, once identified, too seldom treated in people with SMD. After a myocardial infarction, aggressive tertiary prevention may be as effective in people with SMD as in the general population but is less prescribed. Reduced healthcare quality and increased prevalence of cardiovascular risk factors may not fully explain the excess cardiovascular mortality associated with SMDs, which themselves should be considered risk factors in risk calculators. Hazardous health behaviors, the cardio-metabolic adverse effects of medications, and a reduced access to quality healthcare remain priority targets for intervention.
回顾双相情感障碍和精神分裂症(以下简称严重精神障碍,SMD)与心血管发病率和死亡率之间的关联证据,及其机制和降低这种负担的干预措施。
SMD 患者的预期寿命损失在很大程度上仍归因于心血管死亡率。抗精神病药和心境稳定剂与不良的心血管代谢结局相关,但个体间差异很大,而且不治疗 SMD 可能与更大的心血管死亡率相关。经典的可改变心血管危险因素在 SMD 患者中仍然没有得到充分的筛查,一旦确定,治疗也很少。在心肌梗死后,积极的三级预防在 SMD 患者中的效果与在普通人群中一样有效,但处方却更少。降低医疗质量和增加心血管危险因素的流行并不能完全解释与 SMD 相关的心血管死亡率过高,SMD 本身应被视为风险计算器中的危险因素。危险的健康行为、药物的心血管代谢不良影响以及获得高质量医疗保健的机会减少仍然是干预的优先目标。